BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
Number Cited Articles
1
Hourieh Kalhor, Solmaz Sadeghi, Hoda Abolhasani, Reyhaneh Kalhor, Hamzeh Rahimi. Repurposing of the approved small molecule drugs in order to inhibit SARS-CoV-2 S protein and human ACE2 interaction through virtual screening approachesJournal of Biomolecular Structure and Dynamics 2020; : 1 doi: 10.1080/07391102.2020.1824816
2
Kamesh Gupta, Harparam Singh Ghuman, Shivani Vijay Handa. Review of Rifaximin: Latest Treatment Frontier for Irritable Bowel Syndrome Mechanism of Action and Clinical ProfileClinical Medicine Insights: Gastroenterology 2017; 10: 117955221772890 doi: 10.1177/1179552217728905
3
Fernando Magdaleno, Maximilian Joseph Brol, Robert Schierwagen, Frank Erhard Uschner, Michael Zwick, Jonel Trebicka. The Human Gut-Liver-Axis in Health and Disease2019; : 235 doi: 10.1007/978-3-319-98890-0_14
4
Elesa Poteres, Nathaniel Hubert, Sudeep Poludasu, Gabriella Brigando, Julia Moore, Kelly Keeler, Allison Isabelli, Iara Cassandra V. Ibay, Lauren Alt, Matthew Pytynia, Mae Ciancio, Kristina Martinez-Guryn. Selective Regional Alteration of the Gut Microbiota by Diet and AntibioticsFrontiers in Physiology 2020; 11 doi: 10.3389/fphys.2020.00797
5
El-Sayed Ibrahim, Ayman Alsebaey, Hassan Zaghla, Sabry Moawad Abdelmageed, Khalid Gameel, Eman Abdelsameea. Long-term rifaximin therapy as a primary prevention of hepatorenal syndromeEuropean Journal of Gastroenterology & Hepatology 2017; 29(11): 1247 doi: 10.1097/MEG.0000000000000967
6
Ashley Oliver, Mark Wong, Chelsea Sanchez. Role of Rifaximin in Spontaneous Bacterial Peritonitis PreventionSouthern Medical Journal 2018; 111(11): 660 doi: 10.14423/SMJ.0000000000000887
7
Saumya Jayakumar, Rohit Loomba. Review article: emerging role of the gut microbiome in the progression of nonalcoholic fatty liver disease and potential therapeutic implicationsAlimentary Pharmacology & Therapeutics 2019; 50(2): 144 doi: 10.1111/apt.15314
8
S. Böhm, W. Kruis. DivertikulitisDer Internist 2017; 58(7): 745 doi: 10.1007/s00108-017-0266-4
9
Julie Ann Tolefree, Abigail Joy Garcia, Jenee Farrell, Vik Meadows, Lindsey Kennedy, Laura Hargrove, Jennifer Demieville, Nicole Francis, Julia Mirabel, Heather Francis. Alcoholic liver disease and mast cells: What's your gut got to do with it?Liver Research 2019; 3(1): 46 doi: 10.1016/j.livres.2019.02.002
10
L. S. Оrеshkо, E. A. Semenova. Clinical experience with the use of the intestinal antibiotic Rifaximin for celiac diseaseMedical Council 2019; (14): 94 doi: 10.21518/2079-701X-2019-14-94-98
11
Peter Dellatore, Maggie Cheung, Noah Y. Mahpour, Augustine Tawadros, Vinod K. Rustgi. Clinical Manifestations of Hepatic EncephalopathyClinics in Liver Disease 2020; 24(2): 189 doi: 10.1016/j.cld.2020.01.010
12
Guilhem Royer, Fréderic Fourreau, Camille Gomart, Audrey Maurand, Bruno Hacquin, David Ducellier, Florence Cizeau, Stéphane Lo, Catherine Cordonnier-Jourdin, Mélanie Mercier-Darty, Jean-Winoc Decousser. Outbreak of an Uncommon Rifampin-resistant blaNDM-1Citrobacter amalonaticus Strain in a Digestive Rehabilitation Center: The Putative Role of RifaximinClinical Infectious Diseases 2020; 71(5): 1331 doi: 10.1093/cid/ciz1172
13
Rommel Zerpa Alamo, Eamonn M.M. Quigley. Irritable bowel syndrome and colonic diverticular diseaseCurrent Opinion in Gastroenterology 2019; 35(1): 27 doi: 10.1097/MOG.0000000000000499
14
Emma Padilla, Lluis Oms, Elena Espejo, Laura Gómez, Lurdes Pagespetit, Núria Boada, Feliu Bella, Josefa Pérez. Rifampin Resistance in Staphylococci after Rifaximin Intake for Surgical Prophylaxis in Elective Colorectal SurgeryAntimicrobial Agents and Chemotherapy 2018; 62(12) doi: 10.1128/AAC.01353-18